Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therapeutic areas.
Antares Pharma Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$3.83|
|52 Week High||US$2.63|
|52 Week Low||US$5.07|
|1 Month Change||-3.28%|
|3 Month Change||-11.75%|
|1 Year Change||44.53%|
|3 Year Change||13.99%|
|5 Year Change||116.38%|
|Change since IPO||-21.44%|
Recent News & Updates
|ATRS||US Pharmaceuticals||US Market|
Return vs Industry: ATRS exceeded the US Pharmaceuticals industry which returned 13.8% over the past year.
Return vs Market: ATRS exceeded the US Market which returned 36.2% over the past year.
Stable Share Price: ATRS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: ATRS's weekly volatility (5%) has been stable over the past year.
About the Company
Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therapeutic areas. It develops, manufactures, and commercialize novel therapeutic products using its drug delivery systems. The company’s injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate.
Antares Pharma Fundamentals Summary
|ATRS fundamental statistics|
Is ATRS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ATRS income statement (TTM)|
|Cost of Revenue||US$68.46m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.39|
|Net Profit Margin||37.73%|
How did ATRS perform over the long term?See historical performance and comparison
Is Antares Pharma undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ATRS ($3.83) is trading below our estimate of fair value ($18.49)
Significantly Below Fair Value: ATRS is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ATRS is good value based on its PE Ratio (10.1x) compared to the US Pharmaceuticals industry average (22x).
PE vs Market: ATRS is good value based on its PE Ratio (10.1x) compared to the US market (17.7x).
Price to Earnings Growth Ratio
PEG Ratio: ATRS is good value based on its PEG Ratio (0.4x)
Price to Book Ratio
PB vs Industry: ATRS is overvalued based on its PB Ratio (4.9x) compared to the US Pharmaceuticals industry average (3.2x).
How is Antares Pharma forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ATRS's forecast earnings growth (28.4% per year) is above the savings rate (2%).
Earnings vs Market: ATRS's earnings (28.4% per year) are forecast to grow faster than the US market (14.9% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: ATRS's revenue (14.1% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: ATRS's revenue (14.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ATRS's Return on Equity is forecast to be high in 3 years time
How has Antares Pharma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ATRS has a high level of non-cash earnings.
Growing Profit Margin: ATRS's current net profit margins (37.7%) are higher than last year (4%).
Past Earnings Growth Analysis
Earnings Trend: ATRS has become profitable over the past 5 years, growing earnings by 76.3% per year.
Accelerating Growth: ATRS's earnings growth over the past year (1062.4%) exceeds its 5-year average (76.3% per year).
Earnings vs Industry: ATRS earnings growth over the past year (1062.4%) exceeded the Pharmaceuticals industry 17.5%.
Return on Equity
High ROE: ATRS's Return on Equity (48.9%) is considered outstanding.
How is Antares Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: ATRS's short term assets ($128.0M) exceed its short term liabilities ($72.0M).
Long Term Liabilities: ATRS's short term assets ($128.0M) exceed its long term liabilities ($8.6M).
Debt to Equity History and Analysis
Debt Level: ATRS's debt to equity ratio (19.8%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if ATRS's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: ATRS's debt is well covered by operating cash flow (78.3%).
Interest Coverage: ATRS's interest payments on its debt are well covered by EBIT (6.3x coverage).
What is Antares Pharma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ATRS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ATRS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ATRS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ATRS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ATRS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Bob Apple (55 yo)
Mr. Robert F. Apple, also known as Bob, has been the Chief Executive Officer and President of Antares Pharma Inc. since January 25, 2016. Mr. Apple served as Chief Operating Officer of Antares Pharma Inc....
CEO Compensation Analysis
Compensation vs Market: Bob's total compensation ($USD3.75M) is above average for companies of similar size in the US market ($USD2.35M).
Compensation vs Earnings: Bob's compensation has been consistent with company performance over the past year.
Experienced Management: ATRS's management team is considered experienced (4.9 years average tenure).
Experienced Board: ATRS's board of directors are considered experienced (8.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.3%.
Antares Pharma, Inc.'s employee growth, exchange listings and data sources
- Name: Antares Pharma, Inc.
- Ticker: ATRS
- Exchange: NasdaqCM
- Founded: 1978
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$635.679m
- Shares outstanding: 169.97m
- Website: https://www.antarespharma.com
Number of Employees
- Antares Pharma, Inc.
- 100 Princeton South
- Suite 300
- New Jersey
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/23 22:59|
|End of Day Share Price||2021/09/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.